The declaration of Helsinki: An update on paragraph 30

CMAJ. Canadian Medical Association Journal

Volumn 173, Issue 9, 2005, Pages 1052-1053

  Blackmer, Jeff ^a,c   Haddad, Henry ^b  

^a CMA's Office of Ethics   (Canada)

^b CMA

^c CMAJ   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; EPIDEMIC; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MEDICAL RESEARCH; NOTE; PUBLICATION; WORLD HEALTH ORGANIZATION;

EID: 27544482422     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.045280     Document Type: Note

References (6)

1. Tri-Council policy statement: ethical conduct for research involving humans. Ottawa: Medical Research Council of Canada, Natural Sciences and Engineering Research Council and Social Sciences and Humanities Research Council of Canada. Available: www.ncehr-cnerh.org/english/code_2 (accessed 2004 Sept 21).
2. World Health Organization. Guidelines for good clinical practice (GCP) for trials on pharmaceutical products. WHO Technical Report Series no. 850, 1995, Annex 3.
3. World Medical Association. Declaration of Helsinki: ethical principals for research involving human subjects. As amended in Tokyo, 2004. Ferney-Voltaire, France: The Association; 2004. Available: www.wma.net/e/ ethicsunit/helsinki.htm (accessed 2005 Sept 26).
4. Sacca L. Placebo in clinical research: a continual compromise between ethical requirements and scientific rigor. Ann Ital Med Int 2002;17(4):215-20.
5. Dismantling the Helsinki declaration [editorial]. CMAJ 2003;169(10):997.
6. Angell M. Investigators' responsibilities for human subjects in developing countries. N Engl J Med 2000;342(13)967-9.